- Home
- EQ vs OCEA Comparison
EQ vs OCEA Comparison
Compare EQ & OCEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- OCEA
- Stock Information
- Founded
- EQ 2017
- OCEA 2019
- Country
- EQ United States
- OCEA United States
- Employees
- EQ N/A
- OCEA N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- OCEA Biotechnology: Pharmaceutical Preparations
- Sector
- EQ Health Care
- OCEA Health Care
- Exchange
- EQ Nasdaq
- OCEA Nasdaq
- Market Cap
- EQ 24.8M
- OCEA 20.5M
- IPO Year
- EQ 2018
- OCEA N/A
- Fundamental
- Price
- EQ $0.63
- OCEA $0.47
- Analyst Decision
- EQ Buy
- OCEA
- Analyst Count
- EQ 2
- OCEA 0
- Target Price
- EQ $5.00
- OCEA N/A
- AVG Volume (30 Days)
- EQ 130.9K
- OCEA 631.6K
- Earning Date
- EQ 11-13-2024
- OCEA 01-13-2025
- Dividend Yield
- EQ N/A
- OCEA N/A
- EPS Growth
- EQ N/A
- OCEA N/A
- EPS
- EQ N/A
- OCEA N/A
- Revenue
- EQ $45,914,000.00
- OCEA N/A
- Revenue This Year
- EQ $4.76
- OCEA N/A
- Revenue Next Year
- EQ N/A
- OCEA N/A
- P/E Ratio
- EQ N/A
- OCEA N/A
- Revenue Growth
- EQ 7.70
- OCEA N/A
- 52 Week Low
- EQ $0.49
- OCEA $0.43
- 52 Week High
- EQ $3.25
- OCEA $7.79
- Technical
- Relative Strength Index (RSI)
- EQ 37.33
- OCEA 34.89
- Support Level
- EQ $0.49
- OCEA $0.53
- Resistance Level
- EQ $0.73
- OCEA $0.70
- Average True Range (ATR)
- EQ 0.08
- OCEA 0.08
- MACD
- EQ -0.01
- OCEA -0.02
- Stochastic Oscillator
- EQ 38.92
- OCEA 10.28
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.